Drug profile · INN
crizotinib
XALKORI
crizotinib (XALKORI) is a hepatocyte growth factor receptor inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — crizotinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 9
- Data quality
- 0.84
Quick answer
crizotinib (XALKORI) is a hepatocyte growth factor receptor inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Hepatocyte growth factor receptor inhibitor
Primary target: ALK tyrosine kinase receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Roche's Alecensa Secures Expanded Approval in Japan for ALK-Positive Lung Cancer
Roche has secured an expanded approval for Alecensa in Japan, broadening its therapeutic reach for patients with ALK-positive non-small cell lung cancer. This development underscores Roche's commitment to advancing targeted therapies in oncology.
Ensartinib Phase 3 Results: Market Impact in ALK-Positive NSCLC US
The Phase 3 results of Ensartinib demonstrate promising efficacy in ALK-positive NSCLC, potentially reshaping treatment options and market dynamics in the US.
Treatment Sequencing in NSCLC: Insights from EU Guidelines and ESMO
This article delves into the latest EU guidelines and ESMO recommendations on treatment sequencing for non-small cell lung cancer (NSCLC), highlighting osimertinib's role.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is crizotinib?
crizotinib (XALKORI) is a hepatocyte growth factor receptor inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for crizotinib?
XALKORI is a marketed brand name for crizotinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of crizotinib?
crizotinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.